SEOM clinical guidelines for the treatment of follicular non-Hodgkin’s lymphoma
| Autor: | A. Rueda Domínguez, J. Guma I Padro, M. Provencio Pulla, D. Rodriguez Abreu, J. Alfaro Lizaso, C. Quero Blanco, M. Llanos Muñoz, J. Gomez Codina, N. Martinez Banaclocha, L. de la Cruz Merino |
|---|---|
| Jazyk: | angličtina |
| Předmět: |
Oncology
medicine.medical_specialty Pathology Cancer Research Allogeneic transplantation Follicular lymphoma Clinical Guides in Oncology Disease Medical Oncology Follicular non-Hodgkin's lymphoma Internal medicine hemic and lymphatic diseases Medicine Combined Modality Therapy Humans Follicular non-Hodgkin’s lymphoma Stage (cooking) Early Detection of Cancer Societies Medical Neoplasm Staging Clinical Trials as Topic business.industry Lymphoma Non-Hodgkin Disease Management General Medicine medicine.disease Prognosis Lymphoma Natural history Practice Guidelines as Topic Rituximab Non-Hodgkin lymphoma therapy business Oncohematology malignancies medicine.drug |
| Zdroj: | Clinical & Translational Oncology CLINICAL & TRANSLATIONAL ONCOLOGY r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe instname |
| ISSN: | 1699-048X |
| DOI: | 10.1007/s12094-015-1437-1 |
| Popis: | Follicular non-Hodgkin's lymphoma (FL) is a nodal B lymphoid malignancy that originates from the germinal center of a lymph node. FL is the second most frequent lymphoma subtype. The course of the disease is usually characterised by a typically indolent clinical course, with a median survival rate of 8-10 years, although most patients relapse after treatment. Diagnosis should always be based on a surgical specimen like an excisional node lymph biopsy. The first-line treatment of FL will depend of extension disease, tumour burden, patient symptoms, performance status and also patient decision. The addition of rituximab to conventional chemotherapy has improved ORR, PFS and OS. As first line in patients that need treatment, a combination of chemotherapy with rituximab induction followed by 2 years of rituximab maintenance is the best option. High-dose chemotherapy with autologous stem-cell transplantation in first line has not shown improvement and is not recommended as first-line therapy. Before any treatment decision in relapsed patients, a repeat biopsy is mandatory to rule out a transformation into large cell aggressive lymphoma. Standard treatment is controversial, depends on the efficacy of prior treatment, duration of the time-to-relapse, patient's age and histological findings at relapse. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|